Last week the U.S. Commercial Service hosted a virtual roundtable discussion on how to facilitate and build a stronger health industry. Leadership from the Norwegian Ministry of Finance, the Ministry of Trade and Industry, and the Ministry of Health and Care Services, and the U.S. Embassy joined experts from the U.S. life science sector, including Pfizer, Janssen, AbbVie, Roche, Bristol Myers Squibb, Biogen, GE Healthcare, MSD/ Merck, Inc., plus the Association of the Pharmaceutical Industry in Norway (LMI), and the American Chamber of Commerce in Norway.
Chargé Shawn Crowley provided introductory remarks and reaffirmed the pledge of the Biden-Harris Administration to pursue a trade and investment policy that helps the economy recover from the COVID pandemic and reinforces long-term investments to strengthen domestic production of essential medical equipment, expand industrial capacity, promote long-term supply chain resiliency, and bolster preparation to tackle future public health crises. One of the priorities of the U.S. Embassy is to continue to advance the trade and investment relationship between Norway and the United States. U.S. life science companies provide a significant contribution to the Norwegian health industry as manufacturers of innovative medical technologies, through investments in research and development, and through joint venture partnerships with Norwegian companies. We are working together to further health industry collaboration, including through establishing new partnerships on research, innovation, and clinical trials to advance patient outcomes in the health care sector.